PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11270941

Omalizumab.

S Easthope·B Jarvis
View original source ↗Export metadata ↓

Abstract

* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic patients treated with omalizumab. * Omalizumab was also effective in the treatment of children with allergic asthma demonstrating improvements in health-related quality-of-life and significant dosage reductions of inhaled corticosteroids. * Administration of omalizumab to patients with allergic rhinitis resulted in a rapid dose-dependent suppression of serum free IgE levels. * Omalizumab significantly improved health-related quality-of-life and nasal symptoms in patients with seasonal allergic rhinitis. Antihistamine requirements were also significantly reduced following treatment. * Adverse events were infrequent in clinical trials of omalizumab, and not significantly different from placebo. The most frequent drug-related event was mild to moderate urticaria.

Explore related subjects

Anti-Allergic AgentsAnti-Asthmatic AgentsAntibodies, Anti-IdiotypicAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAsthmaHistamine AntagonistsHistamine ReleaseHumansImmunoglobulin EOmalizumabRhinitis, Allergic, SeasonalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Easthope, B Jarvis. 2001. Omalizumab.. https://doi.org/10.2165/00003495-200161020-00008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Application of TPX polymer membranes for the controlled release of triprolidine.

Oral administration of triprolidine, antihistamines, may cause many adverse effects such as dry mouth, sedation, dizziness and transdermal drug delivery was considered. Poly(4-methyl-1-pentene) (TPX) membrane, which has good mechanical strength was fabricated by the casting method. TPX membranes was a little brittle and the plasticizers was added for preparing the membranes. The present study was carried out to evaluate the possibility of using the polymer TPX membrane as a controlling membrane and further develop a TPX matrix system for transdermal delivery of triprolidine. The effects of molecular weights of TPX, plasticizers, polyethylene glycol (PEG) 400, drug concentration, and temperature on drug release were studied. The solubility of triprolidine increased exponentially as the increased volume fraction of PEG 400 in saline, and the rate of permeation through TPX membrane was proportional to PEG 400 volume fraction. The release rate of drug from the TPX matrix increased with increased temperature and drug concentration. Among the plasticizers used such as alkyl citrates, phthalates and sebacate, tetra ethyl citrate (TEC) showed the best enhancing effects. Enhancement factor of TEC was 3.76 from TPX matrix at 37 degrees C. The transdermal controlled release of triprolidine system could be developed using the TPX polymer including the plasticizer.

Anti-Allergic Agents↗
PubMed2002

Pharmacological approaches.

Treatment of moderate to severe atopic disease may require multidrug regimens, reflecting the multifaceted nature of allergic inflammation. Furthermore, despite the central role of Th2 inflammation in allergic rhinitis (15), asthma (14), and atopic dermatitis (11), specific mediator antagonists may not be uniformly successful in the treatment of all atopic disorders. For example, antihistamines are very effective treatment for the symptoms of allergic rhinitis (41), but have minimal benefit in the treatment of asthma (42-44). Current research efforts are ongoing to identify and develop therapies aimed at critical junctures in the immunopathological process. For example, animal studies have suggested that IL-4 and IL-13 are two cytokines that are pivotal in the generation of airway allergic inflammation. Blocking the action of these cytokines may markedly decrease the allergic inflammation (17,125).

Anti-Allergic Agents↗